Effect of mutalysin II on vascular recanalization after thrombosis induction in the ear of the hairless mice model

Toxicon

Volumn 50, Issue 5, 2007, Pages 698-706

  Agero, Ubirajara ^a   Arantes, Rosa M E ^a   Lacerda Queiroz, Norinne ^b   Mesquita, Oscar N ^a   Magalhaes A ^c   Sanchez, Eladio F ^c,d   Carvalho Tavares, Juliana ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Laboratório de Limnologia Instituto de Ciências Biológicas ICB   (Brazil)

^c FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^d Programa de Pos Graduacao e Pesquisa   (Brazil)

Author keywords

Ear microcirculation; Intravital microscopy; Lachesis muta venom; Mutalysin II; Thrombolysis

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; MERCURY; MUTALYSIN II; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VENOMBIN A;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HAIRLESS MOUSE; IN VIVO STUDY; LIGHT EXPOSURE; MICROCIRCULATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; THROMBOSIS;

ANIMALS; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; EAR, EXTERNAL; FEMALE; FIBRINOLYTIC AGENTS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED HRS; MICROCIRCULATION; THROMBOSIS; VASCULAR PATENCY; VIPER VENOMS; VIPERIDAE;

ANIMALIA; LACHESIS MUTA; LACHESIS MUTA MUTA; MUS;

EID: 34548666793     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2007.06.003     Document Type: Article

References (30)

1. Bello C.A., Hermogenes A.L.N., Magalhaes A., Veiga S.S., Gremski L.H., Richardson M., and Sanchez E.F. Isolation and biochemical characterization of a fibrinolytic proteinase from Bothrops leucurus (white tailed jararaca) snake venom. Biochimie 88 (2006) 189-200
2. Bertolino G., Noris P., Previtali M., Gamba G., Ferrario M., Montani N., and Balduini C.L. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am. J. Cardiol. 69 (1992) 457-461
3. Collen M.D. Fibrin-selectivity thrombolytic therapy for acute myocardial infarction. Circulation 93 (1996) 857-865
4. Collen M.D. Role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology 2001 (2001) 1-9
5. Didisheim P., and Lewis J.H. Fibrinolytic and coagulant activities of certain snake venoms and proteases. Proc. Soc. Exp. Biol. Med. 93 (1956) 10-13
6. Estevão-Costa M.I., Diniz C.E., Magalhães A., Markland F.S., and Sanchez E.F. Action of metalloproteinases mutalysin I and II on several components of the hemostatic and fibrinolytic systems. Thromb. Res. 99 (2000) 363-376
7. Furie B., and Furie B.C. Thrombus formation in vivo. J. Clin. Invest. 115 (2005) 3355-3362
8. Gasmi A., Chabchoub A., Guermazi S., Karoui H., Elayeb M., and Dellagi K. Further characterization and thrombolytic activity in a rat model of fibrinogenase from Vipera lebetina venom. Thromb. Res. 86 (1997) 233-242
9. Hong T.-T., Huang J., and Lucchesi B.R. Effect of thrombolysis on myocardial injury: recombinant and tissue plasminogen activator vs. alfimeprase. Am. J. Physiol.-Heart. Circ. Physiol. 290 (2006) H959-H967
10. Lian Q., Szarka S.J., Ng K.K.S., and Wong S.-L. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots. J. Biol. Chem. 278 (2003) 26677-26686
11. Lijnen H.R., and Collen D. Strategies for the improvement of thrombolytic agents. Thromb. Haemost. 66 (1991) 88-106
12. Markland F.S., Friederichs G.S., Pewitt S.R., and Lucchesi B.R. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 90 (1994) 2448-2456
13. Moll S., Kenyon P., Bertoli L., De Maio J., Homesley H., and Deitcher S.R. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J. Clin. Oncol. 24 19 (2006) 3056-3060
14. Ouriel K., Cynamon J., Weaver F.A., Dardik H., Akers D., Blebea J., Gruneiro L., Toombs C.F., Wang-Clow F., Molher M., Pena L., Wan C.-Y., and Deitcher S.R. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J. Vas. Interv. Radiol. 16 (2005) 1075-1083
15. Parise P., Hauert J., Iorio A., Callegari P., and Agnelli G. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. J. Lab. Clin. Med. 125 (1995) 212-221
16. Ramos H.P., and Selistrede Araujo H.S. Comparative analysis of the catalytic domain of hemorrhagic and non-hemorrhagic snake venom metallopeptidases using bioinformatic tools. Toxicon 44 (2004) 529-538
17. Roesken F., Rueker M., Vollmar B., Boeckel N., Morgenstern E., and Menger M.D. A new model for quantitative in vivo microscopic analysis of thrombus formation and vascular recanalisation: the ear of the hairless (hr/hr) mouse. Thromb. Haemost. 78 (1997) 1408-1414
18. Roesken F., Vollmar B., Rucker M., Seiffge D., and Menger M.D. In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization. J. Vasc. Surg. 28 (1998) 498-505
19. Rucavado A., Sanchez E.F., Franceschi A., Magalhaes A., and Gutierrez J.M. Characterization of the local tissue damage induced by LHF-II, a metalloproteinase with weak hemorrhagic activity isolated from Lachesis muta muta snake venom. Toxicon 37 (1999) 1297-1312
20. Sanchez E.F. Mutalysins. In: Barrett A.J., Rawlings N.D., and Woessner F.J. (Eds). Handbook of Proteolytic Enzymes (2004), Elsevier, New York 692-694 (Chapter 198)
21. Sanchez E.F., and Swenson S. Proteases from South American snake venoms affecting fibrinolysis. Curr. Pharm. Anal. 3 (2007) 147-157
22. Sanchez E.F., Magalhães A., Mandelbaum F.R., and Diniz C.R. Purification and characterization of hemorrhagic factor II from the venom of the bushmaster snake (Lachesis muta muta). Biochim. Biophys. Acta 1074 (1991) 347-356
23. Sanchez, E.F., Gabriel, L.M., Gontijo, S., Gremski, L.H., Veiga, S.S., Evangelista, K.S., Eble, J.A., Richardson, M., 2007. Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom. Arch. Biochem. Biophys., submitted.
24. Swenson S., and Markland F.S. Snake venom fibrin(ogen)olytic enzymes. Toxicon 45 (2005) 1021-1039
25. Swenson S., Toombs C.F., Pena L., Johansson J., and Markland F.S. α-Fibrinogenases. Curr. Drug. Targets-Cardiovasc. Hematol. Dis. 4 (2004) 417-434
26. Souza C.T., Moura M.B., Magalhaes A., Heneine L.G., Olortegui C.C., Diniz C.R., and Sanchez E.F. Inhibition of mutalysin II, a metalloproteinase from bushmaster snake venom by human α2-macroglobulin and rabbit immunoglobulin. Comp. Biochem. Physiol. B-Biochem. Mol. Biol. 130 (2001) 155-168
27. Stocker W., Grams F., Baumann U., Reinemer P., Gomis-Ruth F.-X., McKay D.B., and Bode W. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 4 (1995) 823-840
28. ten Cate H., Schoenmakers S.H., Franco R., Timmerman J.J., Groot A.P., Spek C.A., and Reistma P.H. Microvascular coagulopathy and disseminated intravascular coagulation. Crit. Care Med. 29 Suppl. 7 (2001) S95-S98
29. Toombs C.F. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 31 (2001) 141-147
30. Toombs C.F. New directions in thrombolytic therapy. Curr. Opin. Pharmacol. 1 (2001) 164-168